Kymera Investor Presentation Deck
HS: Significant Reductions in AN Counts Leading to HiSCR Responses
Mean % Change (+/- S.E. of mean)
-10
-20
-30
40
-50
-60
Mean % Change in Total AN
Counts Over time
0 7
KYMERA
-27.4
-19.9
14
-49.6
21
Day
-31.6
28
-45.4
All HS Patients (N=12)*
Moderate to Severe (N=10)
-40.6
35
-46.11
-50.7
42
©2023 KYMERA THERAPEUTICS, INC.
% of Patients with AN 0/1/2 (80% CI)
80
70
60
50
40
30
20
10
O
0
7
% of Patients
with AN Count 0/1/2
20
14
17
21
Day
50
28
42
50
35
All HS Patients (N=12)
Moderate to Severe (N=10)
42
40
33
42
% of HISCR Responders (80% CI)
80
70
60
50
40
30
20
10
O
HISCR50 Responders
7
30
14
25
21
Day
30
*One patient is censored for Day 35 and Day 42 since the patient started on ustekinumab, steroids and abx on Day 34.
28
25
All HS Patients (N=12)
Moderate to Severe (N=10)
50
42
35
50
42
42
PAGE 25View entire presentation